Last Updated : June 1, 2023
Details
FilesGeneric Name:
vericiguat
Project Status:
Active
Therapeutic Area:
Heart failure
Manufacturer:
Bayer Inc.
Call for patient/clinician input open:
Brand Name:
Verquvo
Project Line:
Reimbursement Review
Project Number:
SR0758-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Bayer requests VERQUVO be reimbursed for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent heart failure decompensation event requiring hospitalization and/or intravenous diuretic therapy. VERQUVO should be used in combination with standard of care therapy for heart failure. Initiation criteria: In adult patients with New York Heart Association (NYHA) II to IV chronic HF Other HF therapies include an angiotensin-converting enzyme inhibitor (ACEi), an angiotensin II receptor antagonist (ARB) or an angiotensin receptor and neprilysin inhibitor (ARNi), a beta-blocker, and if tolerated, a mineralocorticoid receptor antagonist (MRA) VERQUVO should be initiated under the supervision of a healthcare professional who is experienced in the management of HF.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
VERQUVO (vericiguat) is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent heart failure decompensation event requiring hospitalization and/or intravenous diuretic therapy. VERQUVO should be used in combination with standard of care therapy for heart failure.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | September 15, 2022 |
|---|---|
| Call for patient/clinician input closed | November 04, 2022 |
| Clarification: - Patient input submission received from HeartLife Foundation and Heart function clinic Vancouver General Hospital, St Paul's Hospital | |
| Submission received | October 14, 2022 |
| Submission accepted | October 28, 2022 |
| Review initiated | October 31, 2022 |
| Draft CADTH review report(s) provided to sponsor for comment | January 19, 2023 |
| Deadline for sponsors comments | January 31, 2023 |
| CADTH review report(s) and responses to comments provided to sponsor | March 09, 2023 |
| Expert committee meeting (initial) | March 22, 2023 |
| Draft recommendation issued to sponsor | May 10, 2023 |
| Draft recommendation posted for stakeholder feedback | May 18, 2023 |
| End of feedback period | June 02, 2023 |
Files
Last Updated : June 1, 2023